Want to see SE:MODTX full AI Analyst Report?

Modus Therapeutics Holding AB (MODTX) Price & Analysis

0 Followers

MODTX Stock Chart & Stats

kr0.30

-kr0.02(-1.23%)

At close: Mar 06 4:00 PM EST

kr0.30

-kr0.02(-1.23%)

Day’s Range― - ―

52-Week Rangekr0.21 - kr5.00

Previous CloseN/A

Volume636.00

Average Volume (3M)841.43K

Market Cap

kr45.37M

Enterprise Valuekr30.08M

Total Cash (Recent Filing)kr5.32M

Total Debt (Recent Filing)kr5.00M

Price to Earnings (P/E)―

Beta1.79

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.42

Shares Outstanding121,628,494

10 Day Avg. Volume409,277

30 Day Avg. Volume841,432

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.10

Price to Sales (P/S)0.00

P/FCF Ratio-1.05

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.14

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Precision Rare-disease FocusA concentrated R&D focus on sickle cell disease and related rare hematology conditions creates a durable strategic position: smaller, well-defined patient populations with high unmet need improve the odds of clinical and regulatory pathways and long-term premium pricing if efficacy is proven.

Lead Program Targeting Vaso-occlusive ComplicationsHaving a clear lead program addressing vaso-occlusive crises targets a core morbidity driver in sickle cell disease; success would establish clinical differentiation and meaningful value proposition, supporting durable adoption among specialists and potential for label expansion in related hematologic complications.

Low Leverage (zero Reported Debt)Reported zero debt across recent years preserves financial flexibility and reduces near-term solvency risk, enabling the company to prioritize R&D spend and partnership options without fixed interest burdens, a structural advantage for a pre-revenue biotech reliant on financing cycles.

Bears Say

Persistent Negative Cash GenerationConsistent negative operating and free cash flow, with worsening burn in 2025, creates a durable funding need: the company must secure external capital regularly, which can dilute shareholders, constrain strategic choices, and distract management from long-term R&D execution.

Pre-revenue, No Near-term Revenue VisibilityBeing pre-revenue with no indicated commercialization timeline means limited internal cash generation and uncertain pathway to profit. This structural profile increases reliance on successful trials or partnerships to create durable revenue streams and long-term business sustainability.

Equity Volatility And Dilution RiskVolatile equity and past recapitalizations signal recurring financing rounds. For a clinical-stage biotech, repeated dilution risk can erode shareholder value and complicate long-term planning, while dependence on capital markets or partners raises execution risk if financing conditions tighten.

MODTX FAQ

What was Modus Therapeutics Holding AB’s price range in the past 12 months?

Modus Therapeutics Holding AB lowest stock price was kr0.21 and its highest was kr5.00 in the past 12 months.

What is Modus Therapeutics Holding AB’s market cap?

Modus Therapeutics Holding AB’s market cap is kr45.37M.

When is Modus Therapeutics Holding AB’s upcoming earnings report date?

Modus Therapeutics Holding AB’s upcoming earnings report date is Aug 26, 2026 which is in 58 days.

How were Modus Therapeutics Holding AB’s earnings last quarter?

Modus Therapeutics Holding AB released its earnings results on May 26, 2026. The company reported -kr0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.027.

Is Modus Therapeutics Holding AB overvalued?

According to Wall Street analysts Modus Therapeutics Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Modus Therapeutics Holding AB pay dividends?

Modus Therapeutics Holding AB does not currently pay dividends.

What is Modus Therapeutics Holding AB’s EPS estimate?

Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Modus Therapeutics Holding AB have?

Modus Therapeutics Holding AB has 121,628,494 shares outstanding.

What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?

Modus Therapeutics Holding AB reported an EPS of -kr0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.065%.

Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?

Currently, no hedge funds are holding shares in SE:MODTX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Modus Therapeutics Holding AB

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.